Modified AAV Vectors Enhance Transgene Expression in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, such as chemotherapy, radiotherapy, and biotherapy, are ineffective for many tumor types, especially in advanced stages, and the application of genetic engineering of lymphocytes to target tumors is limited by the lack of identifiable molecules on solid tumors for specific binding and destruction.
Innovation Solution
Modified adeno-associated viral vectors with specific mutations in the VP1 and VP3 regions are used to enhance cellular therapy by increasing transgene expression in cells, allowing for improved immunotherapy approaches, including the use of CRISPR systems for genomic disruption and chimeric antigen receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type AAV vectors are used for gene delivery, then viral safety and immunogenicity are maintained, but transgene expression levels are insufficient for effective cancer therapy
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the AAV capsid proteins (VP1, VP2, VP3) to alter viral properties. Mutations at positions such as VP1-129 (F to L), VP2-584 (L to N/D), and VP3-642 (H to N) are introduced to enhance transgene expression while maintaining viral safety and reducing immunogenicity, directly resolving the contradiction between safety and productivity
2Ease of manufacture
If conventional cancer therapies (chemotherapy, radiotherapy, biotherapy) are used, then treatment can be administered, but effectiveness is limited especially in advanced stages
Solution Approach 1:
The patent uses modified AAV vectors as intermediaries to deliver therapeutic genes (such as CARs, TCRs, or other transgenes) to target cancer cells. The AAV capsid mutations enable the vector to effectively mediate gene delivery to tumor cells, overcoming the limitations of conventional therapies and providing a new mechanism for cancer treatment that is particularly effective in advanced stages
3Productivity
If AAV capsid mutations are introduced to enhance transduction, then transgene expression increases, but risk of immunogenicity and viral safety issues may increase
Solution Approach 1:
The patent applies local quality by making targeted, specific amino acid substitutions at defined positions in the capsid proteins rather than global modifications. The mutations at specific residues (VP1-129, VP2-584, VP3-642) are carefully selected to locally alter capsid properties for enhanced transduction while preserving overall capsid structure and reducing immunogenicity, thus resolving the contradiction between transduction efficiency and safety
Data Source
AI summary
Genetically modified compositions, such as adeno-associated viral vectors and primary cells, for treating various conditions and diseases. Disclosed are also modified adeno-associated viruses for the treatment of cancer. Also disclosed are the methods of making and using the genetically modified compositions in treating various diseases, conditions, and cancer.